The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1047
ISSUE1047
February 26, 1999
Rifapentine--A Long-Acting Rifamycin for Tuberculosis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Rifapentine--A Long-Acting Rifamycin for Tuberculosis
February 26, 1999 (Issue: 1047)
Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.